Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;49(suppl8):509. doi:10.3322/caac.21492
   Web of Science ®Google Scholar
• Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28 Suppl 1(S1):S24–S31. doi:10.1038/onc.2009.19819680293
   PubMed Web of Science ®Google Scholar
• Cabanero M, Sangha R, Sheffield BS, et al. Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. Curr Oncol. 2017;24(2):111–131. doi:10.3747/co.24.352428490925
   PubMed Web of Science ®Google Scholar
• Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011;17(11):3812–3821. doi:10.1158/1078-0432.CCR-10-340821531810
   PubMed Web of Science ®Google Scholar
• Chen K, Yu X, Wang H, et al. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients. Cancer Chemother Pharmacol. 2017;80(6):1179–1187. doi:10.1007/s00280-017-3464-929063948
   PubMed Web of Science ®Google Scholar
• Pilotto S, Rossi A, Vavalà T, et al. Outcomes of first-generation EGFR-TKIs against non-small-cell lung cancer harboring uncommon EGFR mutations: a post hoc analysis of the BE-POSITIVE study. Clin Lung Cancer. 2018;19(1):93–104. doi:10.1016/j.cllc.2017.05.01628645631
   PubMed Web of Science ®Google Scholar
• Morgillo F, Corte Della CM, Fasano M, Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1(3):e000060–10. doi:10.1136/esmoopen-2016-00006027843613
   PubMed Web of Science ®Google Scholar
• Tetsu O, Hangauer MJ, Phuchareon J, Eisele DW, McCormick F. Drug resistance to EGFR inhibitors in lung cancer. Chemotherapy. 2016;61(5):223–235. doi:10.1159/00044336826910730
   PubMed Web of Science ®Google Scholar
• Nygaard AD, Garm Spindler K-L, Pallisgaard N, Andersen RF, Jakobsen A. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer. 2013;79(3):312–317. doi:10.1016/j.lungcan.2012.11.01623238036
   PubMed Web of Science ®Google Scholar
• Camps C, Jantus-Lewintre E, Cabrera A, et al. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer. 2011;72(3):365–369. doi:10.1016/j.lungcan.2010.09.00521074889
   PubMed Web of Science ®Google Scholar
• Yu HA, Sima CS, Shen R, et al. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015;10(3):431–437. doi:10.1097/JTO.000000000000043225415430
   PubMed Web of Science ®Google Scholar
• Soh J, Toyooka S, Matsuo K, et al. Ethnicity affects EGFRand KRASgene alterations of lung adenocarcinoma. Oncol Lett. 2015;10(3):1775–1782. doi:10.3892/ol.2015.341426622749
   PubMed Web of Science ®Google Scholar
• Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer. 2016;102:122–134. doi:10.1016/j.lungcan.2016.10.01027987580
   PubMed Web of Science ®Google Scholar
• Boch C, Kollmeier J, Roth A, et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open. 2013;3(4):e002560. doi:10.1136/bmjopen-2013-002560
   PubMed Web of Science ®Google Scholar
• Jackman DM, Miller VA, Cioffredi L-A, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009;15(16):5267–5273. doi:10.1158/1078-0432.CCR-09-088819671843
   PubMed Web of Science ®Google Scholar
• Takamochi K, Oh S, Suzuki K. Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers. Oncol Lett. 2013;6(5):1207–1212. doi:10.3892/ol.2013.155124179496
   PubMed Web of Science ®Google Scholar
• Zheng D, Wang R, Zhang Y, et al. The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. Ott. 2016;9:833–843. doi:10.2147/OTT.S96834
   Web of Science ®Google Scholar
• Wen Y-S, Cai L, Zhang X-W, et al. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma. Medicine. 2014;93(29):e296–10. doi:10.1097/MD.000000000000029625546673
   PubMed Web of Science ®Google Scholar
• Li S, Li L, Zhu Y, et al. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. Br J Cancer. 2014;110(11):2812–2820. doi:10.1038/bjc.2014.21024743704
   PubMed Web of Science ®Google Scholar
• Lohinai Z, Hoda MA, Fabian K, et al. Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma. J Thorac Oncol. 2015;10(5):738–746. doi:10.1097/JTO.000000000000049225664625
   PubMed Web of Science ®Google Scholar
• Sun J-M, Hwang DW, Ahn JS, Ahn M-J, Park K. Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer. Gorlova OY, ed. PLoS One. 2013;8(5):e64816. doi:10.1371/journal.pone.006481623724098
   PubMed Web of Science ®Google Scholar
• Syahruddin E, Wulandari L, Sri Muktiati N, et al. Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients. Lctt. 2018;9:25–34. doi:10.2147/LCTT.S154116
   Web of Science ®Google Scholar
• Aditama TY. Smoking problem in Indonesia. Med J Indones. 2002;11(1):56–65. doi:10.13181/mji.v11i1.52
   Google Scholar
• Kristina SA, Endarti D, Prabandari YS, Ahsan A, Thavorncharoensap M. Burden of cancers related to smoking among the Indonesian population: premature mortality costs and years of potential life lost. Asian Pac J Cancer Prev. 2015;16(16):6903–6908.26514465
   PubMedGoogle Scholar
• Levi M, Prayogi G, Sastranagara F, et al. Clinicopathological associations of K-RAS and N-RAS mutations in Indonesian colorectal cancer cohort. J Gastrointest Canc. 2018;49(2):124–131. doi:10.1007/s12029-016-9901-x
   Web of Science ®Google Scholar
• Dearden S, Stevens J, Wu Y-L, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24(9):2371–2376. doi:10.1093/annonc/mdt20523723294
   PubMed Web of Science ®Google Scholar
• Tseng C-H, Chiang C-J, Tseng J-S, et al. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 2017;8(58):98384–98393. doi:10.18632/oncotarget.2184229228697
   PubMedGoogle Scholar
• Shi Y, Li J, Zhang S, et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology - Mainland China subset analysis of the PIONEER study. Chai KX, ed. PLoS One. 2015;10(11):e0143515. doi:10.1371/journal.pone.014351526599344
   PubMed Web of Science ®Google Scholar
• Shi Y, Au JS-K, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–162. doi:10.1097/JTO.000000000000003324419411
   PubMed Web of Science ®Google Scholar
• Hsiao S-H, Lin S-E, Chou Y-T, et al. Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small-cell lung cancer. Mole Clin Oncol. 2014;2(2):252–258. doi:10.3892/mco.2013.232
   Google Scholar
• Kauffmann-Guerrero D, Huber RM, Reu S, et al. NSCLC patients harbouring rare or complex EGFR mutations are more often smokers and might not benefit from first-line tyrosine kinase inhibitor therapy. Respiration. 2018;95(3):169–176. doi:10.1159/00048417529190621
   PubMed Web of Science ®Google Scholar
• Lohinai Z, Ostoros G, Moldvay J, Dome B, Hegedus B. Differences in the epidemiology of rare EGFR mutations in different populations. J Thorac Oncol. 2016;11(1):e19–e20. doi:10.1016/j.jtho.2015.09.00326762751
   PubMed Web of Science ®Google Scholar
• Kempf E, Rousseau B, Besse B, Paz Ares L. KRAS oncogene in lung cancer: focus on molecularly driven clinical trials. Eur Respir Rev. 2016;25(139):71–76. doi:10.1183/16000617.0071-201526929424
   PubMed Web of Science ®Google Scholar
• Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008;14(18):5731–5734. doi:10.1158/1078-0432.CCR-08-064618794081
   PubMed Web of Science ®Google Scholar
• Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18(22):6169–6177. doi:10.1158/1078-0432.CCR-11-326523014527
   PubMed Web of Science ®Google Scholar
• Mao C, Qiu L-X, Liao R-Y, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer. 2010;69(3):272–278. doi:10.1016/j.lungcan.2009.11.02020022659
   PubMed Web of Science ®Google Scholar
• Sasaki H, Okuda K, Kawano O, et al. Nras and Kras mutation in Japanese lung cancer patients: genotyping analysis using LightCycler. Oncol Rep. 2007;18(3):623–628.17671710
   PubMed Web of Science ®Google Scholar
• Lee B, Lee B, Han G, Kwon MJ, Han J, Choi Y-L. KRAS mutation detection in non-small cell lung cancer using a peptide nucleic acid-mediated polymerase chain reaction clamping method and comparative validation with next-generation sequencing. Korean J Pathol. 2014;48(2):100–107. doi:10.4132/KoreanJPathol.2014.48.2.10024868222
   PubMedGoogle Scholar
• Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 Countries, 1980-2012. Jama. 2014;311(2):183–192. doi:10.1001/jama.2013.28469224399557
   PubMed Web of Science ®Google Scholar
• Benhamou S, Benhamou E, Auquier A, Flamant R. Differential effects of tar content, type of tobacco and use of a filter on lung cancer risk in male cigarette smokers. Int J Epidemiol. 1994;23(3):437–443.7960366
   PubMed Web of Science ®Google Scholar
• Huboyo HS, Lestari P, Tohno S. Modeling indoor PM2.5 air pollution, estimating exposure, and problems associated with rural Indonesian households using wood fuel In: McLellan B, editor. Sustainable Future for Human Security. Vol. 14 Singapore: Springer Singapore; 2017:287–300. doi:10.1007/978-981-10-5433-4_20
   Google Scholar
• Arrieta O, Campos-Parra AD, Zuloaga C, et al. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J Thorac Oncol. 2012;7(8):1228–1234. doi:10.1097/JTO.0b013e3182582a9322659961
   PubMed Web of Science ®Google Scholar
• Lee T, Lee B, Choi Y-L, Han J, Ahn M-J, Um S-W. Non-small cell lung cancer with concomitant EGFR, KRAS, and ALK mutation: clinicopathologic features of 12 cases. J Pathol Transl Med. 2016;50(3):197–203. doi:10.4132/jptm.2016.03.0927086595
   PubMed Web of Science ®Google Scholar
• Hu W, Liu Y, Chen J. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer. Oncotarget. 2017;8(15):25046–25054. doi:10.18632/oncotarget.1533728212572
   PubMedGoogle Scholar
• Ulivi P, Chiadini E, Dazzi C, et al. Nonsquamous, non-small-cell lung cancer patients who carry a double mutation of EGFR, EML4-ALK or KRAS: frequency, clinical-pathological characteristics, and response to therapy. Clin Lung Cancer. 2015:1–7. doi:10.1016/j.cllc.2015.11.004.
   Web of Science ®Google Scholar
• Choughule A, Sharma R, Trivedi V, et al. Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer. Br J Cancer. 2014;111(11):2203–2204. doi:10.1038/bjc.2014.401
   Web of Science ®Google Scholar
• Guibert N, Barlesi F, Descourt R, et al. Characteristics and outcomes of patients with lung cancer harboring multiple molecular alterations: results from the IFCT Study Biomarkers France. J Thorac Oncol. 2017;12(6):963–973. doi:10.1016/j.jtho.2017.02.00128189832
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Stinchcombe TE. KRASMutation: should we test for it, and does it matter? JCO. 2013;31(8):1112–1121. doi:10.1200/JCO.2012.43.0454
   PubMed Web of Science ®Google Scholar
• Kaufman J, Stinchcombe TE. Treatment of KRAS-mutant non-small cell lung cancer: the end of the beginning for targeted therapies. JAMA. 2017;317(18):1835–1837. doi:10.1001/jama.2017.343628492885
   PubMed Web of Science ®Google Scholar